EGFR and non-small cell lung carcinoma: MARIPOSA, a phase III randomized trial, is comparing this combination to osimertinib monotherapy as the first-line treatment for EGFR-mutant NSCLC, and has shown a PFS benefit, though OS data are pending [97].